Summit Therapeutics plc Stock

Summit Therapeutics' (NASDAQ: SMMT) shares are up by more than 1,060% in the last 12 months, thanks to the market's exuberant reaction to the latest sets of clinical trial data produced by the

Growth stocks have consistently outperformed most other asset classes in recent years, cementing their place as essential components of well-balanced portfolios. Their potential for high rewards

Investors looking for stocks that can provide dramatic gains found what they were looking for with a pair of cancer drug developers. From the end of 2023 through the closing bell on Sept. 23, shares

Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of artificial intelligence, and its revenue, earnings, and stock price continue

Thrill-seeking investors can get their fill with the rollercoaster rides provided by clinical-stage biotech stocks. Just look at Summit Therapeutics (NASDAQ: SMMT).

By May 7, 2024, Summit

If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for owning a piece of the business. And in some cases, those valuations can

September has been an exciting time for investors with their fingers on the pulse of cancer drug development. In a nutshell, it looks like the world's top-selling cancer therapy could have a serious

Shares of Summit Therapeutics (NASDAQ: SMMT) rocketed 123.4% higher this week through Thursday trading, according to data from S&P Global Market Intelligence.

A biotech stock surging that much

Shares of Summit Therapeutics (NASDAQ: SMMT) were soaring 22.5% higher as of 11:18 a.m. ET on Thursday. The gain came after the clinical-stage biopharmaceutical company revealed that it entered into

With the Federal Reserve's next meeting just days away, the market has been pouring over any relevant economic data to look for clues on the current state of inflation and the economy as the Fed

Shares of Summit Therapeutics (NASDAQ: SMMT) recently jumped in response to positive clinical trial results for its experimental cancer therapy. Results of the phase 3 Harmoni-2 trial suggest newly

Shares of Eli Lilly (NYSE: LLY) notched a 3.5% gain on Thursday, Aug. 1, after the company reported positive clinical trial results for its increasingly successful weight management treatment. It

Never ignore the power of momentum. Sometimes the fastest-moving objects are the ones that keep on racing ahead.

That could be the case with a select group of stocks that have delivered tremendous

Shares of Summit Therapeutics (NASDAQ: SMMT) were sinking 22.6% as of 11:10 a.m. ET on Tuesday. This sell-off follows a similar steep decline of 22% on Friday after Summit revealed late-stage data